Lipella Pharmaceuticals Inc. Common Stock (LIPO) — Strategic Asset Allocation Index

Latest as of December 2022: 3.2%

Lipella Pharmaceuticals Inc. Common Stock (LIPO) has a Strategic Asset Allocation Index of 3.2% as of December 2022. Strategic assets (PP&E of $150.82K plus long-term investments of $-) total $150.82K, measured against net assets of $4.68 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.

SAAI

3.2%
Strategic Assets / Net Assets

Strategic Assets

$150.82K
PP&E + LT Investments

PP&E

$150.82K
USD

Net Assets

$4.68 Million
USD

Lipella Pharmaceuticals Inc. Common Stock Strategic Asset Allocation Index (2020–2022)

This chart shows how Lipella Pharmaceuticals Inc. Common Stock's Strategic Asset Allocation Index has evolved across 3 annual periods from 2020 to 2022. As of December 2022, the index stands at 3.2%, representing strategic assets of $150.82K against net assets of $4.68 Million USD. Explore LIPO cash generation efficiency to assess how effectively this company generates cash.

Annual Strategic Asset Allocation Index for Lipella Pharmaceuticals Inc. Common Stock (2020–2022)

The table below presents the year-by-year Strategic Asset Allocation Index for Lipella Pharmaceuticals Inc. Common Stock from 2020 to 2022, covering 3 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see LIPO stock market capitalisation.

Year SAAI Strategic Assets (USD) PP&E LT Investments Net Assets Change (pp)
2022 3.2% $150.82K $150.82K $- $4.68 Million ▼ -11.2 pp
2021 14.4% $204.80K $204.80K $- $1.42 Million ▼ -40.8 pp
2020 55.2% $255.59K $255.59K $- $463.32K
pp = percentage points